Search
Reglitazar
go.drugbank.com/drugs/DB04971ExperimentalReglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Linseed oil
go.drugbank.com/drugs/DB11357InvestigationalIt is used in drying processes, and is used in other industrial and commercial applications. It is an indirect additive used in food contact substances. … Other fatty acids contained in linseed oil include palmitic acid, stearic acid, oleic acid and linolenic acid.
Mixtures: Herbs of Gold B Complex Plus SoftgelCategories: Complex MixturesAAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalAAV-AIPL is an adenovirus-associated viral vector serotype 8 containing the human _AIPL1_ gene. … Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.
T487
go.drugbank.com/drugs/DB05474ExperimentalThe formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. … This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia.
VX-702
go.drugbank.com/drugs/DB05470InvestigationalIn the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
SF1126
go.drugbank.com/drugs/DB05210InvestigationalSF1126 is an integrin-targeted PI3 kinase inhibitor.
Polaprezinc
go.drugbank.com/drugs/DB09221InvestigationalIt was determined that polaprezinc may be effective in pressure ulcer treatment [A31856]. … It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308].
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular deg...
Citatuzumab Bogatox
go.drugbank.com/drugs/DB06072InvestigationalVB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests.